An interventional study of Getting Off App in Methamphetamine Abuse and HIV/AIDS, sponsored by Friends Research Institute, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-29.
Sponsored by Friends Research Institute, Inc. · Not applicable, Interventional, and Treatment
A commonly used manualized outpatient methamphetamine intervention for gay and bisexual men, "Getting Off," is being translated into a mobile phone application (i.e., app) available for download through common app marketplaces. The application will provide games, guided lessons, informational support, and resources to gay and bisexual men seeking to reduce their methamphetamine use and risky sexual behaviors.
The research team will conduct formative research to translate the 24 Getting Off sessions from a group-based manual-driven intervention to a computerized app, conduct alpha phase post-development bug testing, conduct beta phase usability pilot testing, and refine the app according to alpha- and beta-phase testing. Four focus groups will provide input on the development of the Getting Off app (further input will be obtained through an ongoing Consumer Advisory Board and usability pilot testing) with: 1) out-of-treatment, methamphetamine-using MSM (n=\~8); 2) methamphetamine-using men who have sex with men (MSM) who are currently in outpatient treatment in the brick-and-mortar Getting Off program at the study site (n=\~8); 3) prior methamphetamine-using MSM with a minimum of one year recovery who have completed a minimum 18/24 sessions (75%) of the brick-and-mortar Getting Off program; and, 4) prior methamphetamine-using MSM with a minimum of one year recovery who have had no previous experience or knowledge of the Getting Off intervention (n=\~8). The focus groups will be structured to provide guidance on translating Getting Off into an app that is responsive to culture (e.g., sexuality; HIV prevention/care including pre-exposure prophylaxis (PrEP) uptake, adherence and persistence, antiretroviral therapy (ART) adherence, viral load suppression) and methamphetamine treatment needs.
Following app development, and to ensure benchmarks have been met, alpha phase testing will uncover and remove unwanted bugs, and beta phase usability pilot testing will be conducted with members of the target population (N=30) to test the feasibility, acceptability, and preliminary effects of the Getting Off app. Furthermore, the pilot testing will be utilized to ensure the functionality of the app (i.e., that the app is user-friendly and all features function appropriately).
Behavioral assessments will be conducted at baseline and at 1-month follow-up.
The study team will then conduct a randomized controlled trial (RCT) to evaluate reductions of methamphetamine use and HIV sexual risk behaviors, and increased advancement along the HIV Prevention or Care Continuum, using three approaches: a) two-arm RCT to determine intervention effects through comparison of the immediate delivery (ID; n=150) and delayed delivery (DD; n=150) arms; b) an observed treatment effects analysis powered for prospective sub-group to compare longitudinal pre/post data from the pooled ID and DD arms (N=300); and, c) a two-arm historical matched comparison design to evaluate the outcomes of the Getting Off app (ID+DD; N=300) relative to a matched sample of participants having previously attended the brick-and-mortar group-based Getting Off intervention (N\~600; total N=900).
Following screening, informed consent and baseline assessments, participants will be randomized into one of two arms: Arm A: Immediate access to the Getting Off app (ID); or, Arm B: Participants will have access to the Getting Off app after a delayed 30-day period (DD). Participants in both arms will receive the same Getting Off app and participants in both arms will be given 30-days to engage with the app. The randomized two-arm repeated measures design will assess participants at 1-, 2- (DD arm only), 3-, 6-, and 9-months post-randomization to determine longitudinal intervention effects, observed treatment effects, and a historical comparison with a matched sample of participants who have attended the brick-and-mortar group-based Getting Off intervention.
2,040 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 272 are open to participants now.
This study's enrollment of 226 is above the median of 105 across 1,543 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →Friends Research Institute, Inc. is the lead sponsor of 44 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Self-identified man who has sex with men (MSM) Any methamphetamine use in the past 365 days Between the ages of 18-65 years Able and willing to provide informed consent.
Exclusion Criteria:
Did not identify as a man who had sex with a man No methamphetamine use in the past 365 days Younger than 18 or older than 65 years Not able or willing to provide informed consent.
Participants randomized into the Immediate Delivery arm (n = 113) receive access to the app immediately upon enrollment, and are given a pre- (baseline) and post- (one month post-baseline) test.
Other: Getting Off App
Participants randomized into the Delayed Delivery arm (n = 113) don't receive access to the app until one month post-baseline. For the RCT portion of the analysis, they will also be assessed at baseline and one month post-baseline (i.e., a pre- and post- prior to app exposure, making them the placebo comparator).
Other: Getting Off App
A mobile phone application based on the "Getting Off" methamphetamine treatment manual. Participants download the app and progress through the sessions of the Getting Off intervention through the administration of games, activities, lessons, quizzes, and tutorials. There are 24 sessions total in the app, each addressing a different component of the methamphetamine treatment process. The fundamental basis of the app is gay-specific cognitive behavioral therapy, with elements of motivational interviewing, social support theory, and health belief model dynamics included.
Methamphetamine Use
Days of participant self-reported methamphetamine use in the past 30 days.
Time frame: from baseline to 9-months post randomization
Methamphetamine Injection
Days participants self-reported methamphetamine injection use in past 30 days
Time frame: From baseline to 9-months post randomization
Condomless Anal Intercourse
Reporting condomless anal intercourse in the past 30 days (yes/no)
Time frame: baseline to 9-months post randomization
Condomless Anal Intercourse While High on Methamphetamine
Reporting condomless anal intercourse while high on methamphetamine in the past 30 days (yes/no)
Time frame: 9-months post randomization
ART Initiation
Starting to receive ART among HIV sero-positive participants who were not on ART at baseline (yes/no)
Time frame: 9-months post randomization
PrEP Initiation
Starting to receive PrEP among HIV sero-negative participants who were not on PrEP at baseline (Yes/No)
Time frame: 9-months post randomization
| Milestone | Immediate Delivery (ID; n=113) | Delayed Delivery (DD; n=113) |
|---|---|---|
| Started | 113 | 113 |
| Completed | 85 | 94 |
| Not completed | 28 | 19 |
Days of participant self-reported methamphetamine use in the past 30 days.
| days | Immediate Delivery (ID) | Delayed Delivery (DD) |
|---|---|---|
| Baseline | 13.6 ± 11.3 | 15.3 ± 11.2 |
| 1 month | 10.9 ± 10.3 | 14.5 ± 11.8 |
| 2 months | — | 14.4 ± 10.7 |
| 3 months | 9.4 ± 10.0 | 13.4 ± 11.6 |
| 6 months | 10.2 ± 10.7 | 13.2 ± 11.6 |
| 9 months | 8.8 ± 9.6 | 11.7 ± 11.5 |
Days participants self-reported methamphetamine injection use in past 30 days
| days | Immediate Delivery (ID) | Delayed Delivery (DD) |
|---|---|---|
| Baseline | 2.2 ± 5.5 | 2.3 ± 5.9 |
| 1 month | 1.2 ± 4.4 | 2.3 ± 5.8 |
| 2 months | — | 2.4 ± 6.1 |
| 3 months | 0.7 ± 2.8 | 1.6 ± 4.6 |
| 6 months | 1.3 ± 4.7 | 1.6 ± 5.4 |
| 9 months | 0.8 ± 2.9 | 0.8 ± 3.4 |
Reporting condomless anal intercourse in the past 30 days (yes/no)
| Participants | Immediate Delivery (ID) | Delayed Delivery (DD) |
|---|---|---|
| Baseline | 63 | 54 |
| 1 month | 40 | 55 |
| 2 months | — | 36 |
| 3 months | 32 | 36 |
| 6 months | 38 | 35 |
| 9 months | 40 | 32 |
Reporting condomless anal intercourse while high on methamphetamine in the past 30 days (yes/no)
| Participants | Immediate Delivery (ID) | Delayed Delivery (DD) |
|---|---|---|
| Baseline | 56 | 49 |
| 1 month | 30 | 42 |
| 2 months | — | 30 |
| 3 months | 26 | 32 |
| 6 months | 26 | 28 |
| 9 months | 26 | 23 |
Starting to receive ART among HIV sero-positive participants who were not on ART at baseline (yes/no)
| Participants | Immediate Delivery (ID) | Delayed Delivery (DD) |
|---|---|---|
| ART Initiation | 2 | 5 |
Starting to receive PrEP among HIV sero-negative participants who were not on PrEP at baseline (Yes/No)
| Participants | Immediate Delivery (ID) | Delayed Delivery (DD) |
|---|---|---|
| PrEP Initiation | 4 | 7 |
Collected over Up to 9 months post randomization. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Immediate Delivery | 0/113 (0%) | 0/113 (0%) | 0/113 (0%) |
| Delayed Delivery | 0/113 (0%) | 0/113 (0%) | 0/113 (0%) |
| Age, Continuous(years) | Immediate Delivery | Delayed Delivery | Total |
|---|---|---|---|
| Mean | 45.3 ± 9.5 | 45.3 ± 10.3 | 45.3 ± 9.9 |
| Sex: Female, Male(Participants) | Immediate Delivery | Delayed Delivery | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 113 | 113 | 226 |
| Ethnicity (NIH/OMB)(Participants) | Immediate Delivery | Delayed Delivery | Total |
|---|---|---|---|
| Hispanic or Latino | 40 | 37 | 77 |
| Not Hispanic or Latino | 63 | 67 | 130 |
| Unknown or Not Reported | 10 | 9 | 19 |
| Race (NIH/OMB)(Participants) | Immediate Delivery | Delayed Delivery | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 3 | 4 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 27 | 29 | 56 |
| White | 52 | 44 | 96 |
| More than one race | 11 | 11 | 22 |
| Unknown or Not Reported | 20 | 24 | 44 |
| Region of Enrollment(Participants) | Immediate Delivery | Delayed Delivery | Total |
|---|---|---|---|
| United States | 113 | 113 | 226 |
| Baseline Methamphetamine Use(days) | Immediate Delivery | Delayed Delivery | Total |
|---|---|---|---|
| Mean | 13.6 ± 11.3 | 14.5 ± 11.8 | 14.4 ± 11.3 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No — No current plan to share IPD.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acquired Immunodeficiency Syndrome→
Friends Research Institute, Inc.